Last reviewed · How we verify
68Ga-NODAGA-Exendin-4
At a glance
| Generic name | 68Ga-NODAGA-Exendin-4 |
|---|---|
| Sponsor | Radboud University Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Visualizing Beta Cells in Patients With a History of Gestational Diabetes (NA)
- A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass (PHASE2)
- GLP1R-imaging in Hypoglycemia (PHASE1)
- Exendin PET/CT for Imaging of Paragangliomas
- BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation (PHASE2)
- GLP1-imaging Before and After Bariatric Surgery (PHASE1, PHASE2)
- 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 68Ga-NODAGA-Exendin-4 CI brief — competitive landscape report
- 68Ga-NODAGA-Exendin-4 updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI